Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

D3 Bio (wuxi) Co., Ltd

Clinical trials sponsored by D3 Bio (wuxi) Co., Ltd, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill targets Hard-to-Treat cancer mutation Results expected Apr 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 4 Not yet recruiting 1 Completed 1

New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers

Disease control Not yet recruiting

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC